Pipeline Insight: Endometriosis - Growing the Patient Population is Key to Unlocking the Market's Co

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2004-07-29

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The current endometriosis market is underdeveloped, due to poor disease awareness and both low presentation and diagnosis rates. Current therapies are limited in terms of efficacy and often have unwanted side effects. This report gives an analysis of the endometriosis market, focusing on key R&D products for the disease and investigating existing treatment practices to highlight unmet needs.


Scope

  • Epidemiology of endometriosis in seven major markets, identifying subpopulations and unmet needs
  • Detailed profiles of drugs in Phase II and above examining clinical data and benchmarked against gold standard using quantitative SWOT analysis
  • Country-specific sales forecasts for the seven major markets, based on IMS MIDAS data covering key ATC classes G3A, G3D, G3H, H1C1 (L2A) and H1C3
  • Extensive secondary research and utilization of licensed and in-house databases supplemented by primary research interviews with key opinion leaders


    • Report Highlights
    The endometriosis market will change dramatically following the patent expiry of key brands Lupron Depot, Zoladex and Suprefact. This presents a challenge for R&D candidates, as pressure on pricing and genericization result in a greater demand for improvements over standard therapies in efficacy, tolerability, side effects and cost-effectiveness.

    With an estimated symptomatic population of six million women, there is a significant latent potential. This is due to patients being lost in the treatment pathway through low presentation and diagnosis rates, compounded by poor disease awareness, as well as a lack of an effective, easily accessible, non-invasive diagnostic tool.

    Although the pipeline is sparse, the unmet need in the market is such that Datamonitor forecasts combined sales of six late-stage R&D candidates of $2.2 bn by 2014. While GnRH antagonists are natural successors to Lupron and Zoladex, Schering AG/TAP's asoprisnil is expected to drive the pipeline and set the new standard in endometriosis treatment.


    Reasons to Purchase

  • Quantify the future size and scope of the market, and the potential for new products
  • Benchmark pipeline drugs against currently marketed products with drug profiles and SWOT analysis
  • Measure the impact of key patent expiries using the forecasting model

    • Table of Contents

    Other users found this report page using the following search terms: endometriosis endometriosis market pipeline expiry patent zoladex lupron endometrion patient population

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.